[Federal Register: April 4, 2005 (Volume 70, Number 63)]
[Notices]
[Page 17124-17125]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr04ap05-134]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 4, 2005, Mallinckrodt
Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Difenoxin (9168)........................... I
Heroin (9200).............................. I
Morphine-N-oxide (9307).................... I
Nicomorphine (9312)........................ I
Normorphine (9313)......................... I
Norlevorphanol (9634)...................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylophenidate (1724).................... II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Etorphine HCL (9059)....................... II
Dihydrocodeine (9120)...................... II
Hydromorphone (9150)....................... II
Oxycodone (9143)........................... II
Diphenoxylate (9170)....................... II
Benzoylecgonine (9180)..................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
Metopon (9260)............................. II
Dextropropoxyphene (9273).................. II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
for internal use and for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to
[[Page 17125]]
DEA Headquarters, Attention: DEA Federal Register Representative/ODL,
2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be
filed no later than June 3, 2005.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-6589 Filed 4-1-05; 8:45 am]
BILLING CODE 4410-09-P